"Freund's Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.
| Descriptor ID |
D005620
|
| MeSH Number(s) |
D20.475
|
| Concept/Terms |
Freund's Adjuvant- Freund's Adjuvant
- Adjuvant, Freund's
- Freunds Adjuvant
- Freund Adjuvant
- Adjuvant, Freund
|
Below are MeSH descriptors whose meaning is more general than "Freund's Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Freund's Adjuvant".
This graph shows the total number of publications written about "Freund's Adjuvant" by people in this website by year, and whether "Freund's Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Freund's Adjuvant" by people in Profiles.
-
Melssen MM, Pollack KE, Meneveau MO, Smolkin ME, Pinczewski J, Koeppel AF, Turner SD, Sol-Church K, Hickman A, Deacon DH, Petroni GR, Slingluff CL. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. Cancer Immunol Immunother. 2021 Aug; 70(8):2151-2164.
-
Pollack KE, Meneveau MO, Melssen MM, Lynch KT, Koeppel AF, Young SJ, Turner S, Kumar P, Sol-Church K, Mauldin IS, Slingluff CL. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J Immunother Cancer. 2020 04; 8(1).
-
Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, Muller AJ, Laury-Kleintop LD, Prendergast GC. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther. 2011 Dec 15; 12(12):1050-8.
-
MacDonald AJ, Tawe W, Leon O, Cao L, Liu J, Oksov Y, Abraham D, Lustigman S. Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity. Parasite Immunol. 2004 Jan; 26(1):53-62.
-
Fawcett PT, Dubbs SB, Fawcett LB, Doughty RA. Induction of humoral manifestations of autoimmunity following intraperitoneal injection of complete Freund's adjuvant in mice. Autoimmunity. 1990; 6(4):249-56.
-
Sherwin WK, Rowlands DT. Development of humoral immunity in lethally irradiated mice reconstituted with fetal liver. J Immunol. 1974 Oct; 113(4):1353-60.
-
Corsi A, D'Ancona S, Revoltella R. [Development of epidermal tumors in mice painted with methylcholanthrene and injected with homologous skin suspensions]. Tumori. 1966 Sep-Oct; 52(5):335-9.
-
Goldner H, Girardi AJ, Hilleman MR. Enhancement in hamsters of virus oncogenesis attending vaccination procedures. Virology. 1965 Oct; 27(2):225-7.